BRPI0516265A - composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente - Google Patents
composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmenteInfo
- Publication number
- BRPI0516265A BRPI0516265A BRPI0516265-3A BRPI0516265A BRPI0516265A BR PI0516265 A BRPI0516265 A BR PI0516265A BR PI0516265 A BRPI0516265 A BR PI0516265A BR PI0516265 A BRPI0516265 A BR PI0516265A
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic agent
- liposomes
- composition
- liposome
- retention
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 10
- 229940124597 therapeutic agent Drugs 0.000 title abstract 8
- 239000002502 liposome Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000014759 maintenance of location Effects 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract 2
- 229910001431 copper ion Inorganic materials 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000002555 ionophore Substances 0.000 abstract 2
- 230000000236 ionophoric effect Effects 0.000 abstract 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 2
- 229960004768 irinotecan Drugs 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSICãO, USO DA MESMA, MéTODO DE AUMENTAR A RETENçãO DE UM AGENTE TERAPêUTICO DENTRO DOS LIPOSSOMAS, FORMULAçãO LIPOSSOMAL, E, USO DE UM AGENTE TERAPêUTICO ENCAPSULADO LIPOSSOMALMENTE. A presente invenção refere-se ao uso de íons de cobre, para obter-se retenção aumentada de um agente terapêutico dentro de um lipossoma. A invenção pode ser empregada para mais eficientemente suprir um agente terapêutico lipossomalmente encapsulado para um local alvo in vitro e in vivo para terapia anticâncer ou outra. O lipossama pode compreender uma solução tampão interna, contendo o agente terapêutico, a solução tendo um pH menor do que 6,5 e, muitíssimo preferivelmente, pH 3,5. Pelo menos parte dos íons cobre são retidos dentro da solução interna. Em uma forma de realização, o agente terapêutico pode ser um medicamento quimioterapêutico, tal como irinotecano. A invenção pode também compreender um ionóforo, para facilitar a carga do medicamento dentro do lipossoma. Em uma forma de realização particular, a combinação do ionóforo A23187 e cobre divalente encapsulado (Cu2+) resultou em uma formulação de irinotecano que exibiu atributos de retenção de medicamento surpreendentemente aperfeiçoados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61594304P | 2004-10-06 | 2004-10-06 | |
| PCT/CA2005/001536 WO2006037230A1 (en) | 2004-10-06 | 2005-10-06 | Liposomes with improved drug retention for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516265A true BRPI0516265A (pt) | 2008-08-26 |
Family
ID=36142279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516265-3A BRPI0516265A (pt) | 2004-10-06 | 2005-10-06 | composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8349360B2 (pt) |
| EP (1) | EP1796729A4 (pt) |
| JP (1) | JP4638500B2 (pt) |
| CN (1) | CN101072588B (pt) |
| AU (1) | AU2005291807B2 (pt) |
| BR (1) | BRPI0516265A (pt) |
| CA (1) | CA2582949A1 (pt) |
| WO (1) | WO2006037230A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5207169B2 (ja) * | 2007-10-18 | 2013-06-12 | 独立行政法人日本原子力研究開発機構 | 電離放射線分解性リポソーム、それを用いたリポソーム製剤、並びにリポソームの調整方法 |
| US9968583B2 (en) | 2009-03-30 | 2018-05-15 | Eisai R & D Management Co., Ltd. | Method of manufacture of liposome composition |
| DK2415470T3 (en) | 2009-03-30 | 2016-09-19 | Eisai R&D Man Co Ltd | liposome |
| EP2453927B1 (en) * | 2009-07-17 | 2019-05-15 | Technical University of Denmark | Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines |
| CN108137694B (zh) | 2015-09-18 | 2022-08-12 | 慕尼黑工业大学 | 整合素αvβ6的配体及其合成和应用 |
| AU2016369977A1 (en) * | 2015-12-15 | 2018-06-21 | British Columbia Cancer Agency Branch | Metal complexed therapeutic agents and lipid-based nanoparticulate formulations thereof |
| US9732303B2 (en) | 2016-01-06 | 2017-08-15 | The Procter & Gamble Company | Microcapsules formed from phosphate esters and compositions containing same |
| US10154947B2 (en) | 2016-01-06 | 2018-12-18 | The Procter & Gamble Company | Antiperspirant composition |
| US9730867B2 (en) | 2016-01-06 | 2017-08-15 | The Procter & Gamble Company | Methods of forming a slurry with microcapsules formed from phosphate esters |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| WO2018167295A1 (en) | 2017-03-17 | 2018-09-20 | Technische Universität München | LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| BR112022025918A2 (pt) | 2020-06-18 | 2023-03-14 | Akagera Medicines Inc | Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos |
| MX2023006056A (es) | 2020-11-25 | 2023-06-06 | Akagera Medicines Inc | Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas. |
| CN116509803A (zh) * | 2022-01-21 | 2023-08-01 | 沈阳药科大学 | 外泌体分泌促进剂和光敏剂共载膜融合脂质体及其制备与应用 |
| KR20250031230A (ko) | 2022-05-25 | 2025-03-06 | 아카제라 메디신즈, 인크. | 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310506A (en) | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5352435A (en) | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
| US5525232A (en) | 1990-03-02 | 1996-06-11 | The Liposome Company, Inc. | Method for entrapment of cationic species in lemellar vesicles |
| AU654835B2 (en) | 1991-07-03 | 1994-11-24 | Nexstar Pharmaceuticals, Inc. | Loading technique for preparing drug containing liposomes |
| WO1996025147A1 (en) | 1995-02-14 | 1996-08-22 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering liposome-loadable drugs |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| WO1998017256A1 (en) | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| US6106858A (en) | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
| AU2001258106A1 (en) * | 2000-05-11 | 2001-11-20 | Celator Technologies Inc. | Lipid carrier compositions for improved drug retention |
| EP1299084B1 (en) * | 2000-06-30 | 2005-11-16 | Inex Pharmaceuticals Corp. | Liposomal antineoplastic drugs and uses thereof |
| CA2455598A1 (en) | 2001-07-27 | 2003-02-13 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
| AU2002325120A1 (en) | 2001-09-10 | 2003-03-24 | Celator Technologies Inc. | Unilamellar vesicles stabilized with short chain hydrophilic polymers |
| US7238367B2 (en) | 2001-10-03 | 2007-07-03 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| ES2272768T3 (es) | 2001-10-03 | 2007-05-01 | Celator Pharmaceuticals Inc | Composiciones para la administracion de combinaciones de farmacos. |
| GB2390953A (en) | 2002-07-15 | 2004-01-21 | King S College London | Controlling a micro cell transmit power to maintain quality of service for nearby devices served by an overlapping macro cell |
| AU2003297001A1 (en) | 2002-09-10 | 2004-04-30 | Dow Corning S.A. | Compositions comprising silicone-in-water emulsions and fragrances and hair care preparations comprising such compositions |
| CA2536612A1 (en) | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination compositions of camptothecins and fluoropyrimidines |
| EP1608338A1 (en) | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| DE602005018043D1 (de) | 2004-05-17 | 2010-01-14 | Tekmira Pharmaceuticals Corp | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung |
-
2005
- 2005-10-06 JP JP2007534983A patent/JP4638500B2/ja not_active Expired - Fee Related
- 2005-10-06 CN CN2005800419071A patent/CN101072588B/zh not_active Expired - Fee Related
- 2005-10-06 EP EP05791552A patent/EP1796729A4/en not_active Withdrawn
- 2005-10-06 WO PCT/CA2005/001536 patent/WO2006037230A1/en not_active Ceased
- 2005-10-06 BR BRPI0516265-3A patent/BRPI0516265A/pt not_active IP Right Cessation
- 2005-10-06 AU AU2005291807A patent/AU2005291807B2/en not_active Ceased
- 2005-10-06 CA CA002582949A patent/CA2582949A1/en not_active Abandoned
- 2005-10-06 US US11/576,595 patent/US8349360B2/en not_active Expired - Fee Related
-
2012
- 2012-12-09 US US13/709,005 patent/US8709474B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20110262524A1 (en) | 2011-10-27 |
| CA2582949A1 (en) | 2006-04-13 |
| US8709474B2 (en) | 2014-04-29 |
| AU2005291807A1 (en) | 2006-04-13 |
| WO2006037230A1 (en) | 2006-04-13 |
| EP1796729A1 (en) | 2007-06-20 |
| EP1796729A4 (en) | 2010-12-08 |
| JP4638500B2 (ja) | 2011-02-23 |
| CN101072588B (zh) | 2012-11-28 |
| US20130136790A1 (en) | 2013-05-30 |
| CN101072588A (zh) | 2007-11-14 |
| US8349360B2 (en) | 2013-01-08 |
| AU2005291807B2 (en) | 2012-04-19 |
| JP2008515817A (ja) | 2008-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0516265A (pt) | composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| DE69531701D1 (de) | Sphingosome mit verbesserter arzneistoffabgage | |
| Yu et al. | Butyrate modification promotes intestinal absorption and hepatic cancer cells targeting of ferroptosis inducer loaded nanoparticle for enhanced hepatocellular carcinoma therapy | |
| NO20014662D0 (no) | Fremgangsmåter og preparater for behandling av faste tumorer | |
| NZ541593A (en) | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | |
| BR0115260A (pt) | Complexos de sn-38 com lipìdeos e seus usos no tratamento de doenças | |
| BR0210056A (pt) | composições e métodos para tratamento de hiperplasia | |
| MY134422A (en) | Platinum derivative pharmaceutical formulations. | |
| ES2249888T3 (es) | Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer. | |
| PL371282A1 (en) | A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer | |
| BRPI0412798A (pt) | uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação | |
| EP2301531A3 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| TR200000576T1 (tr) | Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem | |
| BRPI0414014A (pt) | métodos para distribuição intradérmica de agentes terapêuticos | |
| BR0110837A (pt) | Quimioterapia de combinação | |
| IL194883A0 (en) | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| WO2005025501A3 (en) | Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| BRPI0406634A (pt) | Uso de um anagrelìdeo, anagrelìdeo na forma de base, ou um sal farmaceuticamente aceitável do anagrelìdeo, composição farmacêutica não-oral, e dispositivo médido para administração transdérmica | |
| WO2008049903A3 (en) | Wide-area parasystemic treatment of skin related conditions | |
| DK1276482T3 (da) | Kombinationskemoterapi | |
| WO2001041747A3 (de) | Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |